Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced ...

T cells sit at the center of modern immunotherapy, yet many of the rules that govern their activation, differentiation, dysfunction (e.g., exhaustion), and ...

A brisk look at the iconic U.S. brands, from jeans, jets, tech, and credit, that helped define how America lives, buys and ...

Day to day, we exist in our bodies without thinking much about them. We wake up, eat, move around, and fall asleep again, all ...

Researchers at Ben-Gurion University of the Negev (BGU) have discovered that a gene long known for shaping the skin's ...

Using single-cell epigenomic profiling of immune cells from 110 individuals, researchers show that genetic variation and ...

An international research consortium, led by scientists at VIB and UGent, has developed a new platform that could change how ...

An international research team with strong participation from DTU has developed a new biotechnological platform that makes it possible to test and understand advanced cancer treatments much faster and ...

Capillaroscopy stands out in rheumatology and immunology as a non-invasive, reproducible, and cost-effective method for directly assessing microcirculation, ...

Each year, bacterial infections are responsible for roughly 7.7 million deaths worldwide, with this problem further exacerbated by rising antibiotic resistance. Not only are wound infections ...